Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...
Research and Development Expenses: $39.4 million for the fiscal year ended March 31, 2025, up from $20 million the previous year.
General and Administrative Expenses: $17.1 million for the fiscal year ended March 31, 2025, compared to $14.1 million the previous year.
Net Loss: $51.4 million for the fiscal year ended March 31, 2025, compared to $29.4 million the previous year.
Cash, Cash Equivalents, and Marketable Securities: $80.5 million as of March 31, 2025.
Warning! GuruFocus has detected 3 Warning Signs with VTGN.
Release Date: June 17, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Vistagen Therapeutics Inc (NASDAQ:VTGN) has five clinical-stage pherine product candidates with differentiated mechanisms of action, showing positive results in controlled trials.
The company's lead product candidate, Fasedienol, is in Phase III development for social anxiety disorder (SAD), aiming to become the first FDA-approved acute treatment for SAD.
Vistagen is advancing Itruvone for major depressive disorder (MDD), showing promise without common side effects of traditional antidepressants.
PH80, a pherine product candidate for women's health, is progressing as a potential hormone-free treatment for menopausal hot flashes and premenstrual dysphoric disorder (PMDD).
The company has $80.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025, providing a solid financial position to support ongoing development.
Research and development expenses increased significantly to $39.4 million for the fiscal year ended March 31, 2025, compared to $20 million the previous year.
General and administrative expenses rose to $17.1 million, up from $14.1 million, due to increased headcount and professional fees.
The net loss attributable to common shareholders was $51.4 million, a substantial increase from $29.4 million the previous year.
The timeline for PALISADE-4 trial results has been modestly delayed due to stringent subject eligibility requirements and operational adjustments.
There is uncertainty regarding the FDA's evolving regulatory landscape and its impact on Vistagen's product approvals, despite positive interactions with the agency.
Q: Have you noticed any changes in FDA interactions due to leadership turnover, and what caused the timing adjustment for PALISADE-4? A: Shawn Singh, CEO, noted that no FDA reviewers were affected by the recent staff changes, and they are hiring more experts. The timing adjustment for PALISADE-4 was due to stringent subject eligibility requirements and enhanced study execution, which are now showing positive results in screening visits.
Q: Will you announce enrollment completion for PALISADE-3, and how long until top-line data is reported? A: Shawn Singh, CEO, confirmed they will announce when the last patient completes the study. It typically takes about six to eight weeks from database lock to report top-line data.
Q: Can we expect placebo effects in PALISADE-3 and 4 to be similar to PALISADE-2? A: Shawn Singh, CEO, stated that PALISADE-3 and 4 are designed to replicate PALISADE-2's success by limiting variability and enhancing study execution, although actual results will depend on study outcomes.
Q: How are you ensuring proper patient disqualification and scoring consistency in the trials? A: Shawn Singh, CEO, explained that they have an internal secondary eligibility review team to ensure proper execution and scoring, focusing on stringent eligibility criteria and site conduct.
Q: Is there alignment with the FDA on the unmet need for social anxiety disorder treatments like Fasedienol? A: Shawn Singh, CEO, mentioned that while specific program discussions were not allowed at the FDA forum, they have Fast Track designation, indicating FDA's recognition of the unmet need and potential benefits of Fasedienol.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Chocolate company recalls product nationwide for undeclared allergen
NEW YORK (PIX11) — Chocolate products have been recalled nationwide due to potential undeclared milk allergens, according to the U.S. Food and Drug Administration. The Pennsylvania-based distributor, Weaver Nut Company, Inc., has recalled its semi-sweet chocolate nonpareils with white or Christmas colored seeds, the advisory from the FDA says. More Local News People who have an allergy or severe sensitivity to milk could face serious or life-threatening allergic reactions if they consume the impacted products, the FDA warns. So far no illnesses have been reported. The issue was discovered through a wholesale customer who filed a complaint saying the shipment was misaligned with the product specifications. Lab tests confirmed the presence of milk in the product. More: Latest News from Around the Tri-State Consumers who have purchased the recalled product are urged not to eat it if they have a milk allergy and return it to the place of purchase for a full refund. Below is the list of lot codes for the affected chocolates. 47518 – Nonpareil, Semi-Sweet Chocolate (Christmas Seeds) 204206 204207 204208 204209 204212 224225 D2645 – Nonpareils, Semi-Sweet Chocolate (White Seeds) 204214-RL 204214 204215 224221 224222 224223 135215 135216 135217 135220 135221 145204 145205-1 145207-1 145210-1 Dominique Jack is a digital content producer from Brooklyn with more than five years of experience covering news. She joined PIX11 in 2024. More of her work can be found here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Bloomberg
19 minutes ago
- Bloomberg
Ether Leads Crypto Selloff as US Attacks Nuclear Sites in Iran
Ether fell sharply while Bitcoin held steady after President Donald Trump said American bombers and missiles had struck Iran's three main nuclear sites. The second-ranked token fell as much as 7.7% on Sunday morning in Asia to about $2,200, its lowest intra-day level since May 9. Bitcoin briefly dipped below $101,000 but pared losses to trade relatively evenly in the aftermath of the attacks.
Yahoo
19 minutes ago
- Yahoo
Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors
Workiva Inc. (NYSE:WK) is one of the 11 Best Tech Stocks to Buy On the Dip. On May 29, Workiva Inc. (NYSE:WK) announced the appointment of Astha Malik, Chief Business Officer of Braze, to its board of directors. Malik brings 25 years of experience in driving growth and scaling high-growth SaaS companies. The company also released its Q1 2025 results on May 1. The revenue of $206 million grew 17% year-over-year driven by a 20% increase in subscription and support revenue. Both of these financial indicators surpass management's guidance despite a challenging environment characterized by a cautious buying environment and flat professional services revenue. A software engineer debugging a compliance code on a laptop in a modern office setting. After the earnings release, analyst Alexander Sklar from Raymond James maintained an Overweight rating on Workiva Inc. (NYSE:WK) lowering the price target from $125 to $105. The analyst noted the company showed strong bookings in Q1 however, the tough macroeconomic environment led to a conservative outlook by Raymond James. Regardless, Workiva Inc. (NYSE:WK) maintained its full-year revenue guidance at $864 million to $868 million. Workiva Inc. (NYSE:WK) is a technology company that operates a cloud-based platform that enables organizations to streamline and automate financial, sustainability, and compliance reporting processes. Its SaaS platform combines ERP, HCM, and CRM applications, supporting real-time collaboration and integrated reporting across teams. While we acknowledge the potential of WK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Melden Sie sich an, um Ihr Portfolio aufzurufen.
